October 19, 2020 – Philadelphia, PA – We are pleased to announce that Dr. Diya Ren will be joining WuXi Advanced Therapies Unit (WuXi ATU), as Executive Director of CMC, effective October 19, 2020. Dr. Ren brings extensive biopharma industry experience in...
October 5, 2020 – Philadelphia, PA – We are pleased to announce that Jennifer Cheung will be joining WuXi Advanced Therapies Unit (WuXi ATU), as Vice President of Quality Assurance and Regulatory Affairs effective October 5, 2020. Ms. Cheung brings a diverse...
SHANGHAI and PHILADELPHIA, June 1, 2020 — WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announced today the appointment of Dr. David Chang as Chief Executive Officer of WuXi Advanced...
World-class platform will enable biotechnology companies and researchers to accelerate the development, manufacturing and release of cell and gene therapies for patients May 18, 2020 – Philadelphia, PA – WuXi Advanced Therapies, a leading global Contract...
New AAV Vector Suspension platform complements integrated capabilities – enabling cell and gene therapies to be developed, manufactured, and released faster and with greater predictability globally. January 13, 2020 – Philadelphia, PA – WuXi Advanced...
SHANGHAI and SEOUL, South Korea, Nov. 28, 2019 /PRNewswire/ — WuXi ATU Co., Ltd., (WuXi ATU) – a subsidiary of WuXi AppTec, and GeneMedicine – a South Korea-based gene therapy biotechnology company, have formed a strategic partnership for the...
